{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"0.08","value":"0.05"},{"groupId":"OG001","lowerLimit":"0.06","upperLimit":"0.11","value":"0.08"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"515"},{"groupId":"OG001","value":"518"}],"units":"Participants"}],"description":"The mortality rate was determined as the proportion of participants who died by study Day 29. The proportions reported are Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"NUMBER","populationDescription":"The ITT population includes all participants as randomized.","reportingStatus":"POSTED","timeFrame":"Day 1 through Day 29","title":"28-day Participant Mortality","type":"SECONDARY","unitOfMeasure":"proportion of participants"}